You are here

Young Investigator Grants

Young Investigator grants are designed to fill the critical need for startup funds for less experienced researchers to pursue promising research ideas. Eligible applicants may apply during their fellowship training or early in their research careers but must not have achieved an appointment higher than Instructor. These grants encourage and cultivate the best and brightest researchers of the future and lead to long-term research projects. The Young Investigator grant offers up to $60,000 per year for three years.

Lucile Packard Children's Hospital at Stanford University School of Medicine

Background

Principal Investigator Name: 

Yujie Tang, PhD

Project Title: 

Targeting Aberrant Hh Signaling with BET Bromodomain Inhibition as a Novel Therapeutic Strategy Against MB and DIPG

Year Awarded: 

2014

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Dana-Farber Cancer Institute

Background

Principal Investigator Name: 

Kristopher Sarosiek, PhD

Project Title: 

Understanding and Preventing Healthy Tissue Damage in Pediatric Cancer Patients

Year Awarded: 

2014

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Files: 

University of Massachusetts Medical School

Background

Leukemia is one of the most deadly and most common childhood cancers. Current leukemia treatment using non-selective cytotoxic chemotherapy results in a good initial response, but limited long-term survival, likely due to inadequate targeting of deregulated genes.

Project Goal

Principal Investigator Name: 

John Pulikkan, PhD

Project Title: 

Targeted Therapy for Core Binding Factor Leukemia

Year Awarded: 

2014

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Dana-Farber Cancer Institute

Background

Acute myeloid leukemia (AML) accounts for 20% of childhood leukemia and has a long-term survival of only 50%. Thus, new therapies are urgently needed. A new class of drugs, BET bromodomain inhibitors, target proteins that regulate the architecture of DNA and hold significant promise for treatment of pediatric leukemia. At the same time, the relevance of altered metabolism in AML has also come to the forefront. Much work is still needed to effectively implement these discoveries in the clinic.

Project Goal

Principal Investigator Name: 

Yana Pikman, MD

Project Title: 

Translating BET Bromodomain Inhibitors for Acute Myeloid Leukemia Therapy

Year Awarded: 

2014

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Files: 

Lucile Packard Children's Hospital at Stanford University School of Medicine

Background

Long non-coding RNAs (lncRNAs) are RNA sequences that do not encode proteins. In the past, they were regarded as having no biological functions. However, recent studies have shown that lncRNAs regulate a number of cellular activities. More importantly, lncRNAs are beginning to be recognized as key players in oncogenesis in various cancers.

Principal Investigator Name: 

Siu Ping Ngok, PhD

Project Title: 

Investigation of Oncogenic Long Non-coding RNAs in Ewing sarcoma

Year Awarded: 

2014

Cancer Research Category: 

Category of Grant: 

Medical, Nurse Researcher, Quality of LIfe: 

Institution: 

Pages